Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Moderate to Severe Plaque Psoriasis Clear all

Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527

View directory record Official record

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more

Source: ClinicalTrials.gov public record

Updated Oct 17, 2022 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab low dose, secukinumab high dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years

Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more

Source: ClinicalTrials.gov public record

Updated May 15, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional

Bimekizumab in Plaque Psoriasis

NCT06336343

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: East Windsor, New Jersey • New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567

View directory record Official record

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 10, 2022 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

NCT01646177

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Source: ClinicalTrials.gov public record

Updated Jul 27, 2020 · Synced May 21, 2026, 7:59 PM EDT

Recruiting Phase 2 Interventional

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: ORKA-001; Drug
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • Santa Ana, California + 8 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Source: ClinicalTrials.gov public record

Updated Jan 23, 2013 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612

View directory record Official record

Conditions: Plaque-type Psoriasis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jan 3, 2018 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

NCT04713592

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Source: ClinicalTrials.gov public record

Updated Jun 13, 2024 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018

View directory record Official record

Conditions: Chronic Plaque Psoriasis
Interventions: PF-06700841, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 30
States / cities: Rogers, Arkansas • Anaheim, California • Encinitas, California + 18 more

Source: ClinicalTrials.gov public record

Updated Mar 28, 2019 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more

Source: ClinicalTrials.gov public record

Updated Dec 18, 2012 · Synced May 21, 2026, 7:59 PM EDT

Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Source: ClinicalTrials.gov public record

Updated Mar 15, 2022 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865

View directory record Official record

Conditions: Psoriasis
Interventions: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more

Source: ClinicalTrials.gov public record

Updated Jul 6, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: DFD01 Spray, Comp01 Lotion; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years

Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Encinitas, California • Encino, California • Santa Rosa, California + 8 more

Source: ClinicalTrials.gov public record

Updated Mar 6, 2024 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

NCT05190419

View directory record Official record

Conditions: Psoriasis, Skin Diseases
Interventions: Orismilast modified release tablets, Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 15, 2024 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: Stelara, Bmab1200; Biological
Lead sponsor: Biocon Biologics UK Ltd; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Mayfield Heights, Ohio

Source: ClinicalTrials.gov public record

Updated Sep 11, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564

View directory record Official record

Conditions: Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Source: ClinicalTrials.gov public record

Updated Sep 10, 2018 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 50
States / cities: Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more

Source: ClinicalTrials.gov public record

Updated Dec 25, 2018 · Synced May 21, 2026, 7:59 PM EDT

Terminated Phase 3 Interventional

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

NCT00090129

View directory record Official record

Conditions: Arthritis, Psoriatic
Interventions: Onercept, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older

Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 37
States / cities: Little Rock, Arkansas • Fresno, California • Irvine, California + 28 more

Source: ClinicalTrials.gov public record

Updated Oct 21, 2013 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550, Placebo/CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more

Source: ClinicalTrials.gov public record

Updated Sep 18, 2014 · Synced May 21, 2026, 7:59 PM EDT

Active, not recruiting Phase 3 Interventional

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 1,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 74
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more

Source: ClinicalTrials.gov public record

Updated Jan 14, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

NCT03624127

View directory record Official record

Conditions: Psoriasis
Interventions: BMS-986165, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more

Source: ClinicalTrials.gov public record

Updated Jan 29, 2023 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis

NCT01836939

View directory record Official record

Conditions: Psoriasis
Interventions: TSO 2500, TSO 7500; Drug
Lead sponsor: Mark Lebwohl; Other
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Jan 13, 2015 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194

View directory record Official record

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo, Secukinumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 1,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 42
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more

Source: ClinicalTrials.gov public record

Updated Mar 29, 2021 · Synced May 21, 2026, 7:59 PM EDT